Date: 14th April, 2020

To,
The DCS- Listing,
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sub.: Filing of Reports for the quarter ended on 31.03.2020.

Dear Sir,

With reference to various conditions stipulated under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other regulations required to be complied by the listed Companies, we are enclosing herewith the following documents for your record, relating to quarter ended on 31st March, 2020.

1. Regulation 7 (3) – Compliance Certificate certifying maintaining physical & electronic transfer facility.

2. Regulation 74 (5) – Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2018

For Beryl Drugs Limited

Sudhir Sethi
Chairman & Director
DIN: 00090172
April 07, 2020

To
BSE LIMITED
CORPORATE RELATION DEPARTMENT
P J TOWERS,
DALAL STREET,
MUMBAI 400001

Dear Sir/Madam,

Subject: Compliance Certificate - Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ISIN: INE415H01017

Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period October 01, 2019 to March 31, 2020 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Adroit Corporate Services Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number: INR000002227.

We request you to kindly take note of the above in your records.

Thanking you,

For BERYL DRUGS LIMITED

[Signature]

Director/Compliance Officer/Co.Secretary

For ADROIT CORPORATE SERVICES PRIVATE LTD

[Signature]

MR N SURREASH

AGM